Personalized Therapy in IBD: Decoding Disease Heterogeneity and Real-World Evidence

Personalized Therapy in IBD: Decoding Disease Heterogeneity and Real-World Evidence

On-Demand Webcast

Millie D. Long, MD, MPH
University of North Carolina
Chapel Hill, North Carolina


Meenakshi Bewtra, MD, MPH, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Corey A. Siegel, MD, MS
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Target Audience

This educational activity is designed and certified for the entire IBD healthcare team and includes education for gastroenterologists, pediatric gastroenterologists, surgeons, physicians, PhDs, researchers, pharmacists, nurse practitioners, physician assistants, gastroenterology nurses, and residents/fellows/students.


This activity provides clinicians with expert guidance on best-practice updates for the treatment of IBD, including mechanisms of action, safety/efficacy profiles, and optimal use of targeted agents, patient stratification and therapeutic selection, treat-to-target endpoints, and personalization of care for discrete patient populations.


Upon successful completion of this educational activity, participants should be better able to:

  1. Discuss the effects of prior anti-TNF treatment on efficacy data for emerging drug classes
  2. Outline the mechanisms of action and risk/safety profiles of targeted agents for IBD treatment
  3. Develop personalized treatment strategies for patients with IBD based on identified predictive factors for severe disease course
  4. Provide evidence-based rationales for the selection and positioning of IBD therapies based on discrete patient characteristics

Release Date: February 14, 2020

Expiration Date: February 14, 2021

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


This symposium is supported by an educational grant from Pfizer.


 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


NACCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.


This knowledge-based activity (JA0006201-9999-20-085-H01-P) is approved for 1.0 contact hour (0.1 CEU) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Millie D. Long, MD, MPH, Meenakshi Bewtra, MD, MPH, PhD, Corey A. Siegal, MD, MS; and Chris Bolwell, and Lara Gray, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Millie D. Long, MD, MPH, FACG reports that she is a consultant for AbbVie, UCB, Takeda, Pfizer, Janssen, Target PharmaSolutions, Valeant, and Salix

Meenakshi Bewtra, MD, MPH, PhD reports that he is a consultant for Pfizer; has received grant or research support from Takeda; and is a member of the Speaker’s Bureau for Med Learning Group

Corey A. Siegal, MD, MS reports that he is a consultant for Abbvie, Amgen, BMS, Celgene, Lilly, Janssen, Pfizer, Prometheus, Sandoz, Sebela, and Takeda; has received grant or research support from Abbvie, AHRQ, the Crohn’s and Colitis Foundation, Janssen, Pfizer, and Takeda; is a member of the Speaker’s Bureau for Abbvie, Celgene, Janssen, Pfizer, and Takeda; and has received other financial or material support from ColonaryConcepts, LLC, and MiTest Health, LLC.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Lara Gray disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.